The landscape of innovative oncology drug targets
Open Access
- 4 December 2025
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (1) , 104571
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (24JS2840100)
- Higher Education Discipline Innovation Project (B13016)
- Science and Technology Commission of Shanghai Municipality (2023SHZDZX02)
- Fudan University
- National Natural Science Foundation of China (32170657)
- National Natural Science Foundation of China (32470692)
- National Natural Science Foundation of China (32370701)
- National Natural Science Foundation of China (T2425013)
This publication has 7 references indexed in Scilit:
- Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectivesFrontiers in Immunology, 2025
- Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategiesFrontiers in Immunology, 2025
- Patterns of FDA Approval for Novel Oncology DrugsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Tumor biomarkers for diagnosis, prognosis and targeted therapySignal Transduction and Targeted Therapy, 2024
- Next-Generation Sequencing Technology: Current Trends and AdvancementsBiology, 2023
- Bispecific antibodies: a mechanistic review of the pipelineNature Reviews Drug Discovery, 2019
- Improving the efficacy-safety balance of polypharmacology in multi-target drug discoveryExpert Opinion on Drug Discovery, 2017